We are live on ! Find out more
CLRB icon

Cellectar Biosciences
CLRB

16 hedge funds and large institutions have $1.94M invested in Cellectar Biosciences in 2020 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,477% more capital inflows, than outflows

Capital inflows: $398K | Capital outflows: $8.7K

60% more funds holding

Funds holding: 10 → 16 (+6)

1.81% more ownership

Funds ownership: 13.79% → 15.6% (+1.8%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
16
Holders Change
+6
Holders Change %
+60%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FNY Investment Advisers
FNY Investment Advisers
New York
+$155K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$124K
3
Renaissance Technologies
Renaissance Technologies
New York
+$74.3K
4
Citadel Advisors
Citadel Advisors
Florida
+$27.4K
5
Wells Fargo
Wells Fargo
California
+$8.7K

Top Sellers

Rank Fund Capital Flow
1
Game Plan Financial Advisors
Game Plan Financial Advisors
Ohio
-$8.7K

CLRB Hedge Fund Activity: Q1 2020 in Review

16 of the 4,549 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q1 2020, worth a combined $1.94M — down 34% from $2.92M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new CLRB positions and 0 closed out — a net gain of 7 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was FNY Investment Advisers, opening a new position worth an estimated $155K. The largest seller was Game Plan Financial Advisors, cutting an estimated $8.7K.

  • 16 institutional investors held Cellectar Biosciences (CLRB) as of Q1 2020, up from 10 in Q4 2019.
  • Funds reported $1.94M of Cellectar Biosciences stock for Q1 2020, down 34% quarter-over-quarter.
  • 7 funds opened new Cellectar Biosciences positions in Q1 2020 and 0 closed out, a net change of +7 holders.
  • The largest Cellectar Biosciences buyer in Q1 2020 was FNY Investment Advisers, an estimated $155K added.
  • The largest Cellectar Biosciences seller in Q1 2020 was Game Plan Financial Advisors, an estimated $8.7K sold.

Based on aggregated 13F filings for Q1 2020.